ERBB2 and ovarian carcinoma: Newer agents also include antibody‐drug conjugates targeting the HER2 receptor, such as trastuzumab deruxtecan, for which response rates of up to 45% have been reported in ovarian cancer patients with HER2‐positive disease (HER2 3+ or amplification) [75].